
    
      At least 160 healthy Vaccinees will be randomized into 5 ascending dosage cohorts each
      consisting of at least 32 volunteers. In each dosage cohort Vaccinees will be randomly
      assigned to receive 3 doses of either Ad4-H5-Vtn or placebo separated by approximately 56
      days. Volunteers will be followed for 168 days post-third vaccination.
    
  